AgingResearch.NewsJoin free

PTPD2CUFE nanozyme

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funder: National Natural Science Foundation of China
  • Animals1

Outcomes

2

Effects of cellular senescence

downin cells1

1 study

  1. PTPD2CUFE nanozyme decreases effects of cellular senescence in cells.

    “Even an ultralow dose, the therapeutic can still act as a senomorphic, reducing the effects of senescence.”

    Cellsultralow dose

    Combating Atherosclerosis with Chirality/Phase Dual-Engineered Nanozyme Featuring Microenvironment-Programmed Senolytic and Senomorphic Actions

    Advanced materials (Deerfield Beach, Fla.)9 May 2024

Senescent cells

downin cells1

1 study

  1. PTPD2CUFE nanozyme decreases senescent cells in cells.

    “the senolytic performance of D-handed PtPd2CuFe across several aging models is confirmed.”

    Cellsacross several aging modelsD-handed

    Combating Atherosclerosis with Chirality/Phase Dual-Engineered Nanozyme Featuring Microenvironment-Programmed Senolytic and Senomorphic Actions

    Advanced materials (Deerfield Beach, Fla.)9 May 2024

Latest

Related